Bacil Pharma Share Price

Sebi resolves 4,239 investor complaints via SCORES platform in April

Divis Lab Q4 PAT climbs 23% YoY to Rs 662 cr; recommends final dividend of Rs 30/ share

J.G.Chemicals consolidated net profit rises 17.27% in the March 2025 quarter

WEP Solutions standalone net profit declines 17.43% in the March 2025 quarter

Premier Polyfilm standalone net profit declines 16.57% in the March 2025 quarter

Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve 1. Approval of the Audited Financial Results of the Company for the quarter and Yearly ended 31st March 2025;2. Any other business with the permission of Chairperson.

<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Bacil Pharma Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24200MH1987PLC043427</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2024-2025</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>NA</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>NA</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Bhavana Tak</td></tr><tr><td>Designation :-</td><td>Company Secretary and Compliance officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>JAYESH PATIL</td></tr> <tr><td>Designation : -</td><td>CFO</td></tr></table><div> <br/> Date: 23/04/2025<br/><br/></div>

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Bacil Pharma Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24200MH1987PLC043427</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Bhavana Tak <br/> Designation: Company Secretary and Compliance officer <br/> EmailId: bacilpha@yahoo.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: JAYESH PATIL <br/> Designation: CFO <br/> EmailId: bacilpha@yahoo.com</div> </div> <div> <br/> Date: 23/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

Compliance Certificate under Reg 74(5) of SEBI (DP) Regulation

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Gulecha Investments & Trading Co Pvt Ltd